---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-001884"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:09:47.470911+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kymera unveils STAT6 degrader KT-621 (Phase 1 in H2 2024) and TYK2 degrader KT-294 (Phase 1 in H1 2025)

## Summary
- KT-621 (STAT6 degrader) expected to enter Phase 1 in H2 2024; preclinical data shows superior efficacy to dupilumab.
- KT-294 (TYK2 degrader) planned to enter Phase 1 in H1 2025; potential to recapitulate TYK2 loss-of-function biology.
- KT-474 (IRAK4 degrader) Phase 2 enrollment in HS and AD expected to complete Q4 2024; topline data H1 2025.
- Both KT-621 and KT-294 are wholly-owned, once-daily oral degraders targeting validated autoimmune pathways.
- Company holds virtual R&D Day on Jan 4, 2024 to present immunology strategy and new preclinical data.

## SEC filing metadata
- accession: 0001193125-24-001884
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524001884/0001193125-24-001884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524001884/d378650d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-001884
- JSON: https://secwatch.observer/filing/0001193125-24-001884.json
- Plain text: https://secwatch.observer/filing/0001193125-24-001884.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.